Pluripotent Transcription Factors Possess Distinct Roles in Normal versus Transformed Human Stem Cells

por Ji, Junfeng, Werbowetski-Ogilvie, Tamra E., Zhong, Bonan, Hong, Seok-Ho, Bhatia, Mickie
Publicado 2009

Cross-species analysis of SHH medulloblastoma models reveals significant inhibitory effects of trametinib on tumor progression

por Borlase, Stephanie, DeCarlo, Alexandria, Coudière-Morrison, Ludivine, Liang, Lisa, Porter, Christopher J., Ramaswamy, Vijay, Werbowetski-Ogilvie, Tamra E.
Publicado 2023

Novel glycolipid agents for killing cisplatin-resistant human epithelial ovarian cancer cells

por Moraya, Amani I., Ali, Jennifer L., Samadder, Pranati, Liang, Lisa, Morrison, Ludivine Coudière, Werbowetski-Ogilvie, Tamra E., Ogunsina, Makanjuola, Schweizer, Frank, Arthur, Gilbert, Nachtigal, Mark W.
Publicado 2017

Characterization of novel biomarkers in selecting for subtype specific medulloblastoma phenotypes

por Liang, Lisa, Aiken, Christopher, McClelland, Robyn, Morrison, Ludivine Coudière, Tatari, Nazanin, Remke, Marc, Ramaswamy, Vijay, Issaivanan, Magimairajan, Ryken, Timothy, Del Bigio, Marc R., Taylor, Michael D., Werbowetski-Ogilvie, Tamra E.
Publicado 2015

Characterization of a novel OTX2‐driven stem cell program in Group 3 and Group 4 medulloblastoma

por Stromecki, Margaret, Tatari, Nazanin, Morrison, Ludivine Coudière, Kaur, Ravinder, Zagozewski, Jamie, Palidwor, Gareth, Ramaswamy, Vijay, Skowron, Patryk, Wölfl, Matthias, Milde, Till, Del Bigio, Marc R., Taylor, Michael D., Werbowetski‐Ogilvie, Tamra E.
Publicado 2018

Metabolism-based targeting of MYC via MPC-SOD2 axis-mediated oxidation promotes cellular differentiation in group 3 medulloblastoma

por Martell, Emma, Kuzmychova, Helgi, Kaul, Esha, Senthil, Harshal, Chowdhury, Subir Roy, Morrison, Ludivine Coudière, Fresnoza, Agnes, Zagozewski, Jamie, Venugopal, Chitra, Anderson, Chris M., Singh, Sheila K., Banerji, Versha, Werbowetski-Ogilvie, Tamra E., Sharif, Tanveer
Publicado 2023

MDB-21. THE OTX2-REGULATED ALTERNATIVE SPLICING LANDSCAPE CONTROLS DIFFERENTIATION AND RECONSTITUTES THE DEVELOPMENTAL ORIGINS OF GROUP 3 MEDULLOBLASTOMA

por Saulnier, Olivier, Zagozewski, Jamie, Liang, Lisa, Hendrikse, Liam D, Gordon, Victor, Aldinger, Kimberly A, Haldipur, Parthiv, Borlase, Stephanie, Coudiere-Morrison, Ludivine, Layug, Paul, Cai, Ting, Porter, Christopher J, Richard, Stephane, Doble, Brad W, Millen, Kathleen J, Taylor, Michael D, Werbowetski-Ogilvie, Tamra E
Publicado 2023

An OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate

por Zagozewski, Jamie, Shahriary, Ghazaleh M., Morrison, Ludivine Coudière, Saulnier, Olivier, Stromecki, Margaret, Fresnoza, Agnes, Palidwor, Gareth, Porter, Christopher J., Forget, Antoine, Ayrault, Olivier, Hawkins, Cynthia, Chan, Jennifer A., Vladoiu, Maria C., Sundaresan, Lakshmikirupa, Arsenio, Janilyn, Taylor, Michael D., Ramaswamy, Vijay, Werbowetski-Ogilvie, Tamra E.
Publicado 2020

Combined MEK and JAK/STAT3 pathway inhibition effectively decreases SHH medulloblastoma tumor progression

por Zagozewski, Jamie, Borlase, Stephanie, Guppy, Brent J., Coudière-Morrison, Ludivine, Shahriary, Ghazaleh M., Gordon, Victor, Liang, Lisa, Cheng, Stephen, Porter, Christopher J., Kelley, Rhonda, Hawkins, Cynthia, Chan, Jennifer A., Liang, Yan, Gong, Jingjing, Nör, Carolina, Saulnier, Olivier, Wechsler-Reya, Robert J., Ramaswamy, Vijay, Werbowetski-Ogilvie, Tamra E.
Publicado 2022